WEST

Generate Collection | Print

FR 2,789,314
8/11/00

L4: Entry 4 of 6 File: DWPI Nov 24, 2001

EFD 1/29/99

DERWENT-ACC-NO: 2000-571850
DERWENT-WEEK: 200231

TITLE: Bioadhesive wound sealing material comprising monomeric, oligomeric and optionally polymeric methylenemalonate compounds, is readily biodegraded to non-toxic components

INVENTOR: BELIARD, I; BRETON, P ; BRU-MAGNIEZ, N ; ROQUES-CARMES, C ; BRU-MAGNIEZ, M ; BRU, M N ; ROQUES, C C

PATENT-ASSIGNEE:

ASSIGNEE	CODE
VIRSOL	VIRSN
VIRSOL SNC	VIRSN

PRIORITY-DATA: 1999FR-0001485 (February 9, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
KR 2001104341 A	November 24, 2001		000	A61L024/06
WO 200047242 A1	August 17, 2000	F	030	A61L024/06
FR 2789314 A1	August 11, 2000		000	A61L017/00
AU 200025543 A	August 29, 2000		000	A61L024/06
EP 1150723 A1	November 7, 2001	F	000	A61L024/06
BR 200008091 A	November 13, 2001		000	A61L024/06
SK 200101077 A3	December 3, 2001		000	A61L024/06
CZ 200102896 A3	January 16, 2002		000	A61L024/06

DESIGNATED-STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
KR2001104341A	August 8, 2001	2001KR-0710027	
WO 200047242A1	February 9, 2000	2000WO-FR00305	
FR 2789314A1	February 9, 1999	1999FR-0001485	
AU 200025543A	February 9, 2000	2000AU-0025543	
AU 200025543A		WO 200047242	Based on
EP 1150723A1	February 9, 2000	2000EP-0903761	
EP 1150723A1	February 9, 2000	2000WO-FR00305	
EP 1150723A1		WO 200047242	Based on
BR 200008091A	February 9, 2000	2000BR-0008091	
BR 200008091A	February 9, 2000	2000WO-FR00305	
BR 200008091A		WO 200047242	Based on
SK 200101077A3	February 9, 2000	2000WO-FR00305	
SK 200101077A3	February 9, 2000	2001SK-0001077	
SK 200101077A3		WO 200047242	Based on
CZ 200102896A3	February 9, 2000	2000WO-FR00305	
CZ 200102896A3	February 9, 2000	2001CZ-0002896	
CZ 200102896A3		WO 200047242	Based on

INT-CL (IPC): A61 L 17/00; A61 L 24/06; C08 F 222/10

ABSTRACTED-PUB-NO: WO 200047242A
BASIC-ABSTRACT:

NOVELTY - A wound sealing material (A) comprises a biocompatible, bioadhesive mixture containing at least 50 wt. % of a methylidenemalonate (MM) based composition (I) comprising (a) 40-100 wt. % monomeric MM compound(s) and/or MM oligomer(s) having molecular weight 6000 or less and (b) 0-60 wt. % MM polymer(s) having molecular weight 6000 or more.

DETAILED DESCRIPTION - A wound sealing material (A) comprises a biocompatible, bioadhesive mixture containing at least 50 (preferably at least 80) wt. % of a composition (I) comprising (a) 40-100 (preferably 50-100) wt. % MM compound(s) of formula CH2=C(X)(Y) (II) and/or MM oligomer(s) having molecular weight 6000 or less and consisting of units of formula -CH2-C(X)(Y)- (III) and (b) 0-60 (preferably 0-50) wt. % MM polymer(s) having molecular weight 6000 or more and consisting of units of formula (III).

X, Y = -COOR1 or -COO(CH2)nCOOR2;

R1, R2 = 1-6C alkyl;

n = 1-5.

An INDEPENDENT CLAIM is included for a novel material (A') having glass transition temperature 0 deg. C or less (preferably -35 to -10 deg. C) containing at least 90 (preferably at least 95) wt. % of MM-based composition (I') comprising (a) 50-90 wt. % MM oligomer(s) having molecular weight 6000 or less and consisting of units (III) and optionally (b) 0-60 (preferably 0-50) wt. % MM polymer(s) having molecular weight 6000 or more and consisting of units (III).

USE - (A) is a bioadhesive useful for joining the edges of wounds (especially fresh dermo-epidermal wounds), preventing bleeding and promoting cicatrization of the damaged tissues. (A) may also contain active agents such as local anesthetics, bacteriostatic agents, antibiotics or analgesics.

ADVANTAGE - (A) has good bioadhesive properties; is easily handled and applied (due to the viscosity properties before and after application); is easily prepared on an industrial scale; has readily controlled physical properties (e.g. viscosity); is easily biodegraded without generating toxic products; and is suitable for application into the interior of the wound and into all of the damaged layers. Typically no inflammatory reactions are observed in 10 days of adhesion. (A) is degraded by bio-erosion to give the non-toxic materials glycolic and ethanol; glycolic acid can even act as a cell growth stimulant.

FR 2,722,411

AN 1996:301292 CAPLUS
DN 124:340926
TI Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies for treating HIV infection
IN Bru-Magniez, Nicole; Cermann, Jean-Claude; Lescure, Francois; Teulon, Jean-marie; Breton, Pascal; Guillon, Xavier
PA Laboratoires Upsa, Fr.; Institut National De La Sante Et De La Recherche Medicale
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM A61K047-48
ICS A61K009-51
CC 15-3 (Immunochemistry)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9602278	A1	19960201	WO 1995-FR960	19950718
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2722411	A1	19960119	FR 1994-8852	19940718
FR 2722411	B1	19961004		
AU 9530798	A1	19960216	AU 1995-30798	19950718
PRAI FR 1994-8852		19940718		
WO 1995-FR960		19950718		

AB Immunonanoparticles consisting of nanoparticles of a polymeric methylidene malonate compd. coated with anti-.beta.2 microglobulin antibodies have been prepd. Preferentially, these nanoparticles have a diam. of 300 nm or less and a mol. wt. between 1500 and 50,000. These compds. can be used alone or in formulations for preventing and/or treating diseases caused by HIV virus infection, as biol. reactants, or in a method for screening for the presence of .beta.2 microglobulin in free form or combined with viral particles in a biol. fluid sample.

ST methylidene malonate nanoparticle beta2 microglobulin antibody; HIV virus infection microglobulin antibody nanoparticle

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunonanoparticles coated with anti-.beta.2 microglobulin monoclonal antibodies for treating and preventing HIV virus infection)

IT Virus, animal
(human immunodeficiency, immunonanoparticles coated with anti-.beta.2 microglobulin monoclonal antibodies for treating and preventing HIV virus infection)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, immunonanoparticles coated with anti-.beta.2 microglobulin

monoclonal antibodies for treating and preventing HIV virus infection)

IT Pharmaceutical dosage forms
(nanoparticles, immunonanoparticles coated with anti-.beta.2 microglobulin monoclonal antibodies for treating and preventing HIV virus infection)

IT Microbicidal and microbiostatic action
(virucidal, immunonanoparticles coated with anti-.beta.2 microglobulin monoclonal antibodies for treating and preventing HIV virus infection)

IT Microglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.2-, immunonanoparticles coated with anti-.beta.2 microglobulin monoclonal antibodies for treating and preventing HIV virus infection)

IT 4442-03-9D, esters 65132-79-8 **116280-23-0**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunonanoparticles coated with anti-.beta.2 microglobulin monoclonal antibodies for treating and preventing HIV virus infection)

RN **116280-23-0** REGISTRY
CN Propanedioic acid, methylene-, 2-ethoxy-2-oxoethyl ethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Methylidene malonate 2.1.2
FS 3D CONCORD
MF C10 H14 O6
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

AN 1994:587250 CAPLUS
DN 121:187250
TI Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles
AU Lescure, Francois; Seguin, Christine; Breton, Pascal; Bourrinet, Philippe; Roy, Didier; Couvreur, Patrick
CS Laboratoire REcherche Galenique, Laboratoires UPSA, Rueil-Malmaison, 92506, Fr.
SO Pharm. Res. (1994), 11(9), 1270-7
CODEN: PHREEB; ISSN: 0724-8741
DT Journal
LA English
CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 35, 36
AB Poly(methylidene malonate 2.1.2.) (PMM 2.1.2.) nanoparticles were prepd. in phosphate buffer through emulsion polymn. of monomeric units; the kinetics of the reaction was monitored by spectrophotometry at 400 nm. Av. nanoparticle sizes, mol. wts. and biodegradability of this potential drug carrier were detd. under various conditions. As previously demonstrated for other similar monomers, i.e. IHCA or IBCA, pH influenced the physicochem. characteristics of the nanoparticles obtained. Ethanol release from the ester-bearing side chains indicated that the polymers were susceptible to hydrolysis when incubated in basic pH or in rat plasma. A secondary degrdn. pathway, yielding formaldehyde through a reverse Knoevenagel's reaction, was minimal. Cytotoxicity studies of this new vector, in vitro, against L929 fibroblast cells demonstrated that PMM 2.1.2. nanoparticles were better tolerated than other poly(alkyl cyanoacrylate) (PACA) carriers. Pharmacokinetic studies were also carried out to observe the fate of 14C-labeled PMM 2.1.2. nanoparticles after i.v. administration to rats. Forty eight-hour post-injection, more than 80% of the radioactivity was received in urine and feces. The body distribution of the polymer was estd. by measuring the radioactivity assocd. with liver, spleen, lung and kidneys. Five minutes after injection, a max. of 24% of the total radioactivity was detected in the liver and less than 0.4% in the spleen. The liver-assocd. radioactivity decrease according to biphasic profile and <8% of the total radioactivity remained after 6 days.
ST polymethylidene malonate nanoparticle prepn; pharmacokinetics polymethylidene malonate nanoparticle
IT Liver
(prepn. and characterization of poly(methylidene malonate) nanoparticles)
IT Polymer degradation
(hydrolytic, prepn. and characterization of poly(methylidene malonate) nanoparticles)
IT Pharmaceutical dosage forms
(nanocapsules, prepn. and characterization of poly(methylidene malonate) nanoparticles)
IT **148184-12-7P**
RL: BPR (Biological process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

RN **148184-12-7** REGISTRY
CN Propanedioic acid, methylene-, 2-ethoxy-2-oxoethyl ethyl ester, homopolymer (9CI) (CA INDEX NAME)
MF (C10 H14 O6)x
CI PMS
PCT Polyvinyl
SR CA
LC STN Files: CA, CAPLUS, IPA, TOXCENTER, USPATFULL

CM 1

CRN 116280-23-0
CMF C10 H14 O6



19 REFERENCES IN FILE CA (1967 TO DATE)
19 REFERENCES IN FILE CAPLUS (1967 TO DATE)

AN 1995:929152 CAPLUS
DN 124:66347
TI New poly(methylidene malonate 2.1.2) nanoparticles: recent developments
AU Breton, P.; Roy, D.; Marchal-Heussler, L.; Seguin, C.; Couvreur, P.; Lescure, F.
CS Laboratoire de Galenique, Laboratoires UPSA, Rueil-Malmaison, 92506, Fr.
SO NATO ASI Ser., Ser. A (1994), Volume Date 1994, 273, 161-72
CODEN: NALSDJ; ISSN: 0258-1213
DT Journal
LA English
CC 63-5 (Pharmaceuticals)
AB Methylidene malonate 2.1.2 monomer [EtO2CC(:CH2)CO2ch2CO2Et] is described as the first example in the use of methylidene malonate to design potential nanoparticle carriers, candidates for drug targeting. The polymer nanoparticles represent a good compromise between biodegradability, which is an important requirement for drug-controlled release systems and toxicity properties.
ST polymethylidene malonate drug delivery
IT Pharmaceutical dosage forms
(nanocapsules, controlled-release; poly(methylidene malonate 2.1.2) nanoparticles)
IT **148184-12-7**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly(methylidene malonate 2.1.2) nanoparticles)

RN **148184-12-7** REGISTRY
CN Propanedioic acid, methylene-, 2-ethoxy-2-oxoethyl ethyl ester, homopolymer (9CI) (CA INDEX NAME)
MF (C10 H14 O6)x
CI PMS
PCT Polyvinyl
SR CA
LC STN Files: CA, CAPLUS, IPA, TOXCENTER, USPATFULL

CM 1

CRN 116280-23-0
CMF C10 H14 O6



19 REFERENCES IN FILE CA (1967 TO DATE)
19 REFERENCES IN FILE CAPLUS (1967 TO DATE)

AN 1998:339420 CAPLUS
DN 129:58710
TI Physicochemical characterization, preparation and performance of poly(methylidene malonate 2.1.2) nanoparticles
AU Breton, P.; Guillon, X.; Roy, D.; Lescure, F.; Riess, G.; Bru, N.; Roques-Carmes, C.
CS VIRSOL, Paris, 75116, Fr.
SO Biomaterials (1998), 19(1-3), 271-281
CODEN: BIMADU; ISSN: 0142-9612
PB Elsevier Science Ltd.
DT Journal
LA English
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 35, 36
AB The present investigation confirms that initially implemented procedure to produce poly(methylidene malonate 2.1.2) (PMM 2.1.2) nanoparticles lead to products mostly contg. plasticizing oligomers which strongly lowered glass transition temp. (Tg), dramatically reduced nanoparticle consistency and rendered them too sensitive to solubilization when dild. in an aq. medium.
From MALDI-TOF spectroscopy anal., performed on intact colloids, emerged some structural information about these oligomeric species which could result from an intramol. cyclization mechanism occurring soon in the course of the polymn. process. Thus, with the objective of overcoming these drawbacks, this contribution deals with the variations of manufg. specifications such as pH and magnetic stirring speed to try and modulate mol. wt. (Mw) of nanoparticle constituents and reduce oligomer concn. Although the analyses performed on these new nanoparticles were rather encouraging, the colloid formation yield became so low that it required the development of other methodologies, excluding a previous emulsion step, and allowing a controlled prodn. of PMM 2.1.2-made nanoparticles having better physicochem. characteristics while keeping good pharmaceutical capabilities.
ST polymethylidene malonate nanoparticle physicochem
IT Drug delivery systems
(nanoparticles; physicochem. characterization and prepn. of poly(methylidene malonate) nanoparticles)
IT Glass transition temperature
Molecular weight
(physicochem. characterization and prepn. of poly(methylidene malonate) nanoparticles)
IT Polymer morphology
(surface; physicochem. characterization and prepn. of poly(methylidene malonate) nanoparticles)
IT **148184-12-7**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(physicochem. characterization and prepn. of poly(methylidene malonate) nanoparticles)

RN **148184-12-7** REGISTRY
CN Propanedioic acid, methylene-, 2-ethoxy-2-oxoethyl ethyl ester, homopolymer (9CI) (CA INDEX NAME)
MF (C10 H14 O6)x
CI PMS
PCT Polyvinyl
SR CA
LC STN Files: CA, CAPLUS, IPA, TOXCENTER, USPATFULL

CM 1

CRN 116280-23-0
CMF C10 H14 O6



19 REFERENCES IN FILE CA (1967 TO DATE)
19 REFERENCES IN FILE CAPLUS (1967 TO DATE)

WEST

End of Result Set

Generate Collection | Print DERWENT 1996-412497

L3: Entry 1 of 1 File: DWPI Aug 22, 2000

DERWENT-ACC-NO: 1996-412497
DERWENT-WEEK: 200042

TITLE: Use of methylene-malonic acid ester for prodn. of gas-filled particles - esp. for prodn. of ultrasound diagnostic agent

INVENTOR: ALBAYRAK, C; ROESSLING, G

PATENT-ASSIGNEE:

ASSIGNEE	CODE
SCHERING AG	SCHD

PRIORITY-DATA: 1995DE-1008049 (February 23, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6106807 A	August 22, 2000		000	A61B008/00
WO 9625954 A1	August 29, 1996	G	017	A61K049/00
DE 19508049 A1	September 12, 1996		005	C07C069/593
DE 19508049 C2	February 6, 1997		005	C07C069/593
EP 804250 A1	November 5, 1997	G	000	A61K049/00
JP 11500435 W	January 12, 1999		013	A61K049/00

DESIGNATED-STATES: CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS:No-Citns.

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
US 6106807A	February 9, 1996	1996WO-EP00538	
US 6106807A	February 23, 1998	1998US-0894593	
US 6106807A		WO 9625954	Based on
WO 9625954A1	February 9, 1996	1996WO-EP00538	
DE 19508049A1	February 23, 1995	1995DE-1008049	
DE 19508049C2	February 23, 1995	1995DE-1008049	
EP 804250A1	February 9, 1996	1996EP-0904032	
EP 804250A1	February 9, 1996	1996WO-EP00538	
EP 804250A1		WO 9625954	Based on
JP 11500435W	February 9, 1996	1996JP-0525343	
JP 11500435W	February 9, 1996	1996WO-EP00538	
JP 11500435W		WO 9625954	Based on

INT-CL (IPC): A61 B 8/00; A61 K 9/50; A61 K 49/00; B01 J 13/02; C07 C 69/593; C07 C 69/73; C08 F 2/18; C08 F 22/14

ABSTRACTED-PUB-NO: US 6106807A
BASIC-ABSTRACT:

The use of methylene-malonic diester derivs. of formula (I) is claimed for prepn. of gas-contg. particles for ultra-sound diagnostics. R1, R2 = opt. unsatd. 1-8C gp. (opt. contg. O (forming ether) and carboxyl gps).

Also claimed is an agent for ultra-sound diagnostics, comprising gas-contg. particles of polymerised symmetrical or asymmetrical (I).

Also claimed is prepn. of particles of polymerised symmetrical or asymmetrical methylenemalonic esters, comprising: (a) dispersing the monomeric methylene malonic ester in an aq. gas-satd. buffer soln., which opt. contains one or more surfactants; (b) dispersing the ester with a stirrer; (c) after polymerisation, sepn. of the resulting gas-contg. particles; (d) opt. washing the particles with water; and (e) taking up the particles in a suspension medium and freeze-drying the particles.

ADVANTAGE - The particles are small and stable, and are well tolerated. They do not agglomerate with each other in water or blood. They are easy and quick to prepare, and give good contrast.
ABSTRACTED-PUB-NO:

WO 9625954A
EQUIVALENT-ABSTRACTS:

The use of methylene-malonic diester derivs. of formula (I) is claimed for prepn. of gas-contg. particles for ultra-sound diagnostics. R1, R2 = opt. unsatd. 1-8C gp. (opt. contg. O (forming ether) and carboxyl gps).

Also claimed is an agent for ultra-sound diagnostics, comprising gas-contg. particles of polymerised symmetrical or asymmetrical (I).

Also claimed is prepn. of particles of polymerised symmetrical or asymmetrical methylenemalonic esters, comprising: (a) dispersing the monomeric methylene malonic ester in an aq. gas-satd. buffer soln., which opt. contains one or more surfactants; (b) dispersing the ester with a stirrer; (c) after polymerisation, sepn. of the resulting gas-contg. particles; (d) opt. washing the particles with water; and (e) taking up the particles in a suspension medium and freeze-drying the particles.

ADVANTAGE - The particles are small and stable, and are well tolerated. They do not agglomerate with each other in water or blood. They are easy and quick to prepare, and give good contrast.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TE RMS: METHYLENE MALONIC ACID ESTER PRODUCE GAS FILLED PARTICLE PRODUCE ULTRASONIC DIAGNOSE AGENT

RN **106392-12-5** REGISTRY
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Adeka 25R1
CN Adeka 25R2
CN Adeka L 61
CN Adeka Pluronic F 108
CN Antarox 17R4
CN Antarox 25R2
CN Antarox B 25
CN Antarox F 108
CN Antarox F 68
CN Antarox F 88
CN Antarox F 88FL
CN Antarox L 61
CN Antarox L 72
CN Antarox P 104
CN Antarox P 84
CN Antarox SC 138
CN Arco Polyol R 2633
CN Arcol E 351
CN B 053
CN BASF-L 101
CN Block polyethylene-polypropylene glycol
CN Block polyoxyethylene-polyoxypropylene
CN Breox BL 19-10
CN Cirrasol ALN-WS
CN Crisvon Assistor SD 14
CN CRL 1005
CN CRL 1605
CN CRL 8131
CN CRL 8142
CN D 500
CN D 500 (polyglycol)
CN Daltocel F 460
CN Detalan
CN DO 97
CN Dowfax 30C05
CN ED 56
CN Empilan P 7068
CN Emulgen PP 230
CN EP 3028
CN Epan 485
CN Epan 710
CN Epan 785
CN Epan U 108
CN Ethylene glycol-propylene glycol block copolymer
CN Ethylene oxide-propylene oxide block copolymer
CN Ethylene oxide-propylene oxide block copolymer dipropylene glycol ether
CN Ethylene oxide-propylene oxide block copolymer ether with ethylene glycol
CN Ethylene oxide-propylene oxide block polymer
CN Ethylene oxide-propylene oxide copolymer, block
CN F 108
CN **Pluronic F 68**
CN **Poloxamer**
CN **Poloxamer 108**
CN **Poloxamer 124**
CN **Poloxamer 182**

CN **Poloxamer 182LF**
CN **Poloxamer 184**
CN **Poloxamer 188**
CN **Poloxamer 231**
CN **Poloxamer 235**
CN **Poloxamer 237**
CN **Poloxamer 238**
CN **Poloxamer 2750**
CN **Poloxamer 282**
CN **Poloxamer 331**
CN **Poloxamer 338**
CN **Poloxamer 401**
CN **Poloxamer 403**
CN **Poloxamer 407**
CN **Poloxamer F 108**
CN **Poloxamer F 127**
CN **Poloxamer F 68**
CN **Poloxamer L 61**
CN **Poloxamer L 64**
CN **Poloxamer P 338**
CN **Poloxamer P 407**
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 11104-97-5, 163516-02-7, 124057-62-1, 121089-00-7, 96639-37-1, 96958-14-4, 99040-06-9, 106138-19-6, 113441-83-1, 115742-90-0, 108688-61-5, 108688-62-6, 37349-41-0, 70226-19-6, 72231-62-0, 77108-15-7, 80456-04-8, 144638-32-4, 83589-65-5, 86904-45-2, 106899-85-8, 107498-07-7, 108340-62-1, 188815-93-2, 211389-05-8, 351002-57-8, 355134-17-7, 406160-61-0
MF (C3 H6 O . C2 H4 O)x
CI PMS, COM
PCT Polyether, Polyether formed
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGU, DRUGUPDATES, IPA, MEDLINE, PDLCOM*, PHAR, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

6363 REFERENCES IN FILE CA (1967 TO DATE)
664 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6371 REFERENCES IN FILE CAPLUS (1967 TO DATE)

```
     (FILE 'HOME' ENTERED AT 13:31:55 ON 07 JUN 2002)

     FILE 'REGISTRY' ENTERED AT 13:32:13 ON 07 JUN 2002
L1             0 S ETHOXYCARBONYL AND METHYLENEOXYCARBONYL(W)ETHENE
L2             0 S METHYLENEOXYCARBONYLETHEN
L3             0 S METHYLENEOXYCARBONYLETHENE
L4             2 S CARBONYLETHENE
L5             1 S METHOXYCARBONYLETHENE
L6             5 S ETHENE(W)DICARBOXYLIC
L7           620 S METHYLENE AND MALONIC AND DIETHYL
L8            89 S (METHYLENE(W)MALON?) AND (DIETHYL(W)ESTER)
L9            87 S DIETHYL AND (METHYLENE(W)MALONATE)

     FILE 'REGISTRY' ENTERED AT 13:49:44 ON 07 JUN 2002
L10            1 S 3377-20-6/RN
L11            1 S ETHOXYCARBONYL? AND METHYLENEMALONATE
L12           37 S METHYLENE AND ETHOXYCARBONYL? AND (MALON!!## OR
ETHYLMALON!!#
L13           64 S METHYLENEMALONATE
L14          150 S C8H10O6/MF
L15            0 S L14 AND METHYLENEMALONATE
L16            1 S L14 AND MALONATE
L17            6 S L14 AND METHOXYCARBONYL
L18            1 S L14 AND ETHENETRICARBOXYLATE
L19            1 S L14 AND ETHENE
L20            1 S L14 AND (CARBOXYLATE OR TRICARBOXYLATE)
L21          150 S L14
L22            1 S L14 AND VINYL
L23            1 S ALLYL AND L14
L24            7 S METHYLIDENEMALONATE

     FILE 'CAPLUS' ENTERED AT 14:25:02 ON 07 JUN 2002
L25            0 S METHYLIDENEMALONATE(W)DIESTER#
L26           25 S METHYLIDENE(W)MALONATE#

     FILE 'REGISTRY' ENTERED AT 14:31:46 ON 07 JUN 2002
L27            0 S PMM(W)(2(W)1(W)2)
L28            1 S MM AND ((2(W)3(W)2) OR 232)

     FILE 'CAPLUS' ENTERED AT 14:33:54 ON 07 JUN 2002

     FILE 'REGISTRY' ENTERED AT 14:34:52 ON 07 JUN 2002
L29            1 S 148184-12-7/RN
L30            1 S 116280-23-0/RN
L31            0 S METHYLIDENE(W)MALONATE(W)(2(W)3(W)2)
L32         6353 S (PROPANEDIOIC(W)ACID) AND METHYLENE
L33         1931 S (PROPANEDIOIC(W)ACID)(3W)METHYLENE
L34            5 S L14 AND (PROPANEDIOIC(W)ACID)

     FILE 'CAPLUS' ENTERED AT 14:42:37 ON 07 JUN 2002
L35            0 S 132786-47-1/RN
L36            1 S 132786-47-1#/RN
L37            7 S 116280-23-0#/RN
L38           19 S 148184-12-7#/RN
```

RN **3377-20-6** REGISTRY
CN Propanedioic acid, methylene-, diethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Malonic acid, methylene-, diethyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN 1,1-Dicarbethoxyethene
CN Diethyl methylenemalonate
CN Ethyl methylenemalonate
CN Methylene diethylmalonate
FS 3D CONCORD
MF C8 H12 O4
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMINFORMRX, CHEMLIST, IFICDB, IFIPAT, IFIUDB, MEDLINE, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

111 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
111 REFERENCES IN FILE CAPLUS (1967 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

RN 132786-47-1 REGISTRY
CN **Propanedioic acid, methylene-, 1-(carboxymethyl) 3-ethyl ester (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C8 H10 O6**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

RN **148184-12-7** REGISTRY
CN Propanedioic acid, methylene-, 2-ethoxy-2-oxoethyl ethyl ester, homopolymer (9CI) (CA INDEX NAME)
MF (C10 H14 O6)x
CI PMS
PCT Polyvinyl
SR CA
LC STN Files: CA, CAPLUS, IPA, TOXCENTER, USPATFULL

CM 1

CRN 116280-23-0
CMF C10 H14 O6



19 REFERENCES IN FILE CA (1967 TO DATE)
19 REFERENCES IN FILE CAPLUS (1967 TO DATE)

WEST Search History

600,895

DATE: Friday, June 07, 2002

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ		
L18	((((methylenemalonate) or (methylene adj2 malonate) or dicarbethoxyethane or (methylene adj diethylmalonate) or (methylene adj diethyl adj malonate)) or (methylene near3 (propanedio??$2))) and ((poly adj (ethyleneoxide or oxyethylene or (ethylene adj oxide)) or polyethyleneoxide or polyoxyethylene or PEO) or ((poly adj vinylpyrrolidone) or polyvinylpyrrolidone or (polyvinyl adj (pyrrolidone or alcohol))) or (poly adj vinyl adj (alcohol or pyrrolidone)) or (PVA or (poly adj3 hydroxypropylmethacrylamide)) or (poly adj3 hydroxypropyl adj methacrylamide) or (poly adj hydroxyethylmethacrylate) or (poly adj hydroxyethyl adj methacrylate) or (polyaminoacid or (poly adj amino adj acid) or (poly adj aminoacid)) or (polylysine or polysaccharide)))	6	L18
	DB=USPT; PLUR=YES; OP=ADJ		
L17	(l14 or l15) near7 (l5 or l6 or l7 or l8 or l9 or l10 or l11 or l12 or l13)	0	L17
L16	(l14 or l15) and (l5 or l6 or l7 or l8 or l9 or l10 or l11 or l12 or l13)	177	L16
L15	methylene near3 (propanedio??$2)	14	L15
L14	(methylenemalonate) or (methylene adj2 malonate) or dicarbethoxyethane or (methylene adj diethylmalonate) or (methylene adj diethyl adj malonate)	412	L14
L13	polylysine or polysaccharide	31998	L13
L12	polyaminoacid or (poly adj amino adj acid) or (poly adj aminoacid)	1260	L12
L11	poly adj hydroxyethyl adj methacrylate	416	L11
L10	poly adj hydroxyethylmethacrylate	145	L10
L9	poly adj3 hydroxypropyl adj methacrylamide	14	L9

L8	PVA or (poly adj3 hydroxypropylmethacrylamide)	9110	L8
L7	poly adj vinyl adj (alcohol or pyrrolidone)	7091	L7
L6	(poly adj vinylpyrrolidone) or polyvinylpyrrolidone or (polyvinyl adj (pyrrolidone or alcohol))	86360	L6
L5	poly adj (ethyleneoxide or oxyethylene or (ethylene adj oxide)) or polyethyleneoxide or polyoxyethylene or PEO	51630	L5
DB=PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ			
L4	(methylidene(w)malonate) or methylidenemalonate	6	L4
DB=USPT; PLUR=YES; OP=ADJ			
L3	(methylidene(w)malonate) or methylidenemalonate	13	L3
L2	(methylidene(w)malonate) or methylidenemalonate	13	L2
DB=DWPI; PLUR=YES; OP=ADJ			
L1	wo-9625954-$.did.	1	L1

END OF SEARCH HISTORY